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P emphigoid (syn herpes) gestationis (PG) is a rare vesicu- lobullous dermatosis of pregnancy, characterized by subepidermal bullae [l]. There are histologic and immu- nologic similarities to bullous pemphigoid (BP) and the term pemphigoid gestationis is therefore a more useful 
term than herpes gestationis, so we will use it in this study. Circulat- 
ing anti-basement membrane zone (BMZ) antibodies may be de- 
tected in the serum of affected patients [2]. We have previously 
identified antigenic cross reactivity between placenta and skin in PG 
[3]. We have suggested that exposure to an antigen present in the 
placenta and expressed in normal placentae from the second trimes- 
ter of pregnancy onwards may be of importance in triggering the 
immune response. 
In addition to circulating antibodies, immunoglobulin and com- 
plement deposition in the cutaneous and placental BMZ may be 
readily identified using conventional immunofluorescent tech- 
niques [4]. 
Antibody binding to BMZ components with subsequent comple- 
ment fixation is thought to be of major pathogenic importance in 
PG [5]. IgG is the most frequently detected anti-BMZ immuno- 
globulin in the serum of patients with PG, but even in some patients 
with no evidence of circulating IgG a “factor” capable of binding 
complement has been found that is detectable by an indirect assay of 
complement binding [6]. This factor has been termed “pemphigoid 
(herpes) gestationis factor” and is thought to be an IgG antibody 
[7,8]. 
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Abbreviations: 
BMZ: Basement membrane zone 
BP: Bullous pemphigoid 
FITC: Fluorescence iso-thiocynate 
F/P Ratio: Fluorescence to protein ratio 
PBS: Phosphate buffered saline 
PF: Pemphigus foliaceous 
PG: Pemphigoid gestationis 
PV: Pemphigus vulgaris 
We have analyzed the distribution of anti-BMZ IgG subclasses in 
the serum, skin, and placental tissue of patients with PG using 
monoclonal antibodies to IgGl, IgG2, IgG3, and IgG4. We com- 
pared the distribution of IgG subclasses in PG to those found in the 
skin and sera from patients with other blistering dermatoses, bullous 
pemphigoid (BP), pemphigus vulgaris (PV), and pemphigus folia- 
ceus (PF). 
MATERIALS AND METHODS 
Patients Thirty patients with PG were studied. The diagnosis had 
been made clinically, supported histologically, and confirmed by 
the presence of IgG and/or C3 in the cutaneous BMZ of peilesional 
skin on direct immunofluorescence. Twelve patients with histolog- 
ically proven BP and 12 patients with histologically proven pem- 
phigus were studied. On clinical and histologic grounds 10 of these 
were classified as PV and two as PF. All 12 patients with BP had 
circulating anti-BMZ antibodies in their sera and all 12 with pem- 
phigus had evidence of circulating intercellular antibodies. 
Tissue Perilesional skin was obtained from five patients with PG, 
12 with BP, 10 with PV, and two with PF. Samples were mounted 
in Ames OCT compound (Ames Co.), snap frozen in liquid nitro- 
gen, and stored in liquid nitrogen until use. 
At delivery, the placentae from four of the affected pregnancies 
from the group of patients with PG were collected. One-centimeter 
cubes of tissue were cut from the amniotic aspect of the placenta 
immediately lateral to the origin of the umbilical cord. In addition, 
l-cm blocks through the umbilical cord were obtained. Placental 
tissue was snap frozen in liquid nitrogen and stored at - 70” C until 
use. 
Serum Serum was collected from all patients during periods of 
disease activity. All serum was alliquoted, snap frozen in liquid 
nitrogen, and stored at - 70°C until use. Serum was stored for up to 
6 months and was not heat treated prior to use. 
Tissue Substrates For the indirect immunofluorescence studies 
normal skin was obtained from 10 healthy adult volunteers with no 
evidence of skin disease. This was mounted in OCT compound, 
snap frozen, and stored in liquid nitrogen at - 190°C until use. A 
representative section was cut and stained with haematoxylin and 
eosin to confirm the orientation of the tissue and then adjacent 
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6-pm thick cryostat sections were cut and used as substrate for indi- 
rect immunofluorescence. 
Immunofluorescence 
Direct Zmmunofluorescence: Standard immunofluorescence tech- 
niques were modified to incorporate use of the monoclonal antibod- 
ies [9]. 6-pm cryostat sections were cut and washed in PBS at pH 7.4 
for 30 min prior to incubation with monoclonal antibodies to IgGl, 
IgG2, IgG3, and IgG4. The antibodies are commercially available 
from Oxoid Diagnostic, U.K. Clone numbers are as follows: IgGl, 
NL16; IgG2, GOM2; IgG3,ZG4; IgG4, RJ4; and antibody speci- 
ficity was determined by haemaglutination inhibition and imprint 
immunofixation following iso-electric focussing. Chess board ti- 
trations were performed on each monoclonal antibody using con- 
trol pemphigus and pemphigoid sera. A titration of 1: 10 was found 
to be optimal for all four monoclonal antibodies used. All antibodies 
were therefore used at a dilution of 1: 10 in phosphate buffered 
saline (PBS) at pH 7.4 and were incubated with the tissue for 30 min 
at 37°C. 
After a 30-min wash with PBS, sections were then incubated with 
FITC labeled rabbit anti-mouse antibody (Dako) and diluted 1: 100 
with PBS, with F : P ratio 2 : 3M, at 37°C for 30 min. A final 30- 
min wash in PBS followed, after which sections were mounted in 
buffered glycerol and examined by fluorescence microscopy. 
In addition, tissue was examined using standard immunofluores- 
cence techniques with a polyclonal antiserum to human IgG (Dako) 
and components of the complement cascade; C3 (Dako), C4, C5, 
Clq, Factor, B and properdin (Atlantic Laboratories, Westbrook, 
MI% 
Indirect Zmmunojluorescence: For indirect immunofluorescence 6-pm 
cryostat sections of tissue substrates were cut as described above. 
These were air dried, rinsed in PBS at pH 7.4, and incubated first 
with patients sera at 37°C for 30 min, then, following further PBS 
rinse, incubated with the monoclonal mouse anti-human antibodies 
as above. After a final PBS rinse sections were mounted in buffered 
glycerol and examined by fluorescence microscopy. Serum was 
screened at a dilution of 1: 10. 
In addition, standard indirect immunofluorescence techniques 
were employed for the detection of circulating IgG using poly- 
clonal IgG (Dako) and f or complement fixation using an indirect 
assay for C3 [lo]. Briefly, 6-pm cryostat sections of tissue were cut 
from frozen blocks of skin as described above, air dried for 15 min, 
and rinsed with PBS for 15 min. Sections were then incubated at 
37°C for 30 min, first with patients sera, washed with PBS for 
15 min, and then incubated at 37°C for 30 min with FITC labeled 
rabbit anti-human IgG (Dako). After a final PBS wash, sections 
were mounted and examined as before. An indirect method to assess 
the complement fixing ability of the serum was employed as de- 
scribed by Hodge [lo]. S ec t ions were sequentially incubated with i) 
patients serum, ii) fresh human serum diluted in complement dilut- 
ing buffer (a source of complement), and iii) FITC labeled rabbit 
anti-human C3. All incubations were for 30 min at 37°C and sec- 
tions were washed for 15 min in PBS between incubations. 
Polyclonal IgG was used at a dilution of 1: 100 (F : P ratio 2 : 3M). 
In order to determine the optimal working dilution, various dilu- 
tions of the conjugate were tested, ranging from 1: 10 to 1: 1000. A 
dilution of 1: 100 was found to give the most reproducible results in 
our laboratory. 
All sections were examined by two independent observers, re- 
cording a positive result as a bright and intense fluorescence. 
Controls 
Tissue: Ten skin biopsies from patients undergoing minor surgical 
procedures were substituted for patients skin in control experi- 
ments. Three full-term placentae from normal pregnancies were 
studied and one placenta from a pregnancy effected by polymorphic 
eruption of pregnancy. These formed the control group for the 
examination of placental tissue. 
Serum: Sera chosen at random from 10 normal, healthy blood 
donors replaced test sera in control experiments. 
RESULTS 
Pemphigoid Gestationis 
Tissue Subclass Distribution: The distribution of the subclasses of 
IgG detected in skin and placenta in PG is shown in Table I. IgGl 
was the predominant autoantibody and was detected in the BMZ of 
all tissue studied (Fig 1). IgG4 and IgG2 were detected in only two 
patients, with IgG2 identified in the skin of one patient and IgG4 in 
the placental BMZ of another patient. 
Serum Subclass Distribution: All the serum examined demonstrated 
complement fixing capacity. The distribution of the various circu- 
lating anti-BMZ IgG subclasses is outlined in Table II. IgGl was 
detected in all the sera examined (Fig 2). The other IgG subclasses 
were detected much less frequently. IgG2 was detected in three sera, 
IgG3 in seven, and IgG4 in four. Serum titrations ranged from 1: 4 
to 1: 128. In those sera in which polyclonal IgG was detected in 
addition to IgGl, the sera titrations were found to be identical. 
Placental Complement Components: In the four placentae studied, 
components of the complement pathway, C3, C4, and C5, were 
found to be deposited. Factor B and properdin were not among 
those components specific to the alternative pathway. Clq was not 
identified in any of the placental tissue. 
Bullous Pemphigoid 
Tissue Subclass Distribution: The distribution of IgG subclasses in 
the perilesional skin of patients with BP is shown in Table I. IgG4 
was the predominant subclass detected in the BMZ, but the distri- 
bution was heterogeneous. IgG4 was the only antibody detected in 
two patients. 
Serum Subclass Distribution: Results of the distribution of the circu- 
lating IgG subclasses in the serum of patients with BP is given in 
Table II. IgG4 was again the most frequently detected subclass and 
was present in all serum examined. IgG2 was not detected. IgG3 
was found in the serum of only two patients. IgGl was present in 
eight sera (75%). Nine sera demonstrated complement fixing abil- 
ity, including serum from one patient in whom only IgG4 could be 
detected. 
Pemphigus 
Tissue Subclass Distribution: The tissue distribution of IgG subclass 
of intercellular autoantibodies is shown in Table II. IgG4 was the 
predominant subclass, present in the skin of all I2 patients with 
pemphigus. IgGl was also frequently observed and was demon- 
strated in both patients with PF and 9/10 with PV. IgG2 was not 
detected and IgG3 was present in only three patients. 
Serum Subclass Distribution: Serum subclass distribution of circulat- 
ing intercellular autoantibodies is given in Table II. IgG4 was de- 
tected in the sera of all patients and IgGl in both with PF and in 
9/10 with PV. IgG2 and IgG3 were each detected in the serum of 
one patient. 
Controls IgG subclasses were not detected in control tissue nor 
sera on immunofluorescence. 
Table I. Tissue IgG Subclass Distribution 
IgG subclass 
Disease (Numberofpatients) IgGl IgG2 IgG3 IgG4 IgG C3 
Skin 
PG (5) 5 1 0 0 2 5 
BP la;’ 8 1 3 12 12 12 
PF 2 0 1 2 2 2 
PV (10) 9 0 2 10 10 10 
Placenta 
PG (4) 4 1 0 1 1 4 
- 
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Figure 1. Direct immunofluorescence with anti-IgGl of placenta from PG patient showing linear BMZ staining in amniotic epithelium (left and of 
normal full-term placenta from control pregnancy showing a negative reaction (right). (X 25) 
DISCUSSION 
Pemphigoid gestationis is now generally considered to be an au- 
toimmune disease. A substance present in the serum of patients with 
PG and which activates complement may be detected using an indi- 
rect assay of complement fixation. This substance is “PG Factor” 
[2]. Jordan [7] showed that PG factor was an autoantibody directed 
against a normal cell surface component of the cutaneous BMZ. 
This antibody was of the IgG class. However, some serum from 
patients who have unequivocal PG do not appear to have circulating 
anti-BMZ IgG antibodies using conventional assays. Carruthers 
[ 1 l] demonstrated that PG factor bound to staphylococcal protein A 
and this, taken with the ability of IgGl to bind complement, sug- 
gested that PG factor might be an IgGl. In spite of sharing a 95% 
sequence homology, the differing subclasses of IgG in man show 
va 
d’ f;)r ing biologic and physical characteristics. Important structural i erences exist between subclasses in terms of number of domains, 
disulphide bonding, and carbohydrate content [12]. In addition, the 
different subclasses demonstrate differing ability to activate com- 
plement, IgGl, and IgG3 activating and binding complement by 
the classical pathway, whereas IgG2 has only a weak classical path- 
way fixing capacity. IgG4 does not activate complement by the 
classical route, although it may have some role in complement 
deposition via the alternative pathway [13]. 
Our study demonstrates that PG factor is an IgGl anti-BMZ 
autoantibody. IgGl was detected in 100% of sera examined from 30 
patients with PG. In only 13 patients (43%) was IgG detected em- 
ploying polyclonal anti-IgG antibodies. Use of monoclonal anti- 
Table II. Serum Subclass Distribution 
IgG Subclass 
Disease (Number ofpatients) IgGl IgG2 IgG3 IgG4 IgG C3 
PG 30 4 6 4 15 30 
BP 8 0 2 12 12 9 
PF (2) 2 0 0 2 2 0 
PV (10) 9 1 1 10 10 8 
bodies appears to provide a more sensitive technique for the detec- 
tion of circulating anti-BMZ antibodies in PG. The tissue 
distribution of IgG autoantibody subclasses in PG appears to corre- 
late with the serum distribution. IgGl is consistently the dominant 
IgG subclass to be detected. This finding has implications for the 
mode of complement activation, because IgGl fixes complement by 
the classical pathway. The results of our investigation of the deposi- 
tion of the complement fragments in the placenta clearly support 
the view that the classical pathway of complement activation is 
being triggered because C4 and C5 are elements of the classical 
complement pathway. Our results for BP, PV, and PF confirm 
earlier reports [14,15] that the distribution of subclasses of IgG 
autoantibodies is heterogeneous. In these diseases IgG4 is the pre- 
dominant antibody, clearly distinguishable from PG where IgGl is 
the dominant antibody. Because the activation and subsequent dep- 
osition of complement was consistently identified in all the tissues 
studied and IgG4 appears unable to bind complement via the classi- 
cal pathway, complement activation may be a secondary phenome- 
non in pemphigoid and pemphigus. Previous studies [16] have sug- 
gested that dermal-epidermal separation in BP occurs as a result of 
immune complex formation and deposition in the BMZ, subse- 
quently resulting in complement activation with recruitment and 
activation of leucocytes. Dahl [17] demonstrated deposition of the 
membrane attack complex of complement in skin biopsies from 
patients with BP and suggested that complement activation in BP 
was proceeding along the classical 
:: 
athway. However, Jordan has 
shown that properdin may be identi ed in the BMZ of patients with 
BP, suggesting that the alternative pathway of complement activa- 
tion is also implicated [18]. 
The role of complement in the genesis of the autoimmune bul- 
lous disorders is not yet fully established. Immune complex activa- 
tion certainly occurs in BP, and it has been suggested that the mech- 
anism for blister formation in BP involves complement activation 
by anti-BMZ antibodies. This then results in the generation of 
various chemotactic factors and leukocyte recruitment, infiltration, 
and degranulation, leading to loss of dermal epidermal adhesion 
[19]. However, Gammon [20] h as measured complement activation 
and immune complex complement mediated chemotaxis in BP. His 
group considered that functionally significant production of com- 
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Figure 2. Indirect immunofluorescence on full-term placenta (substrate) with anti-IgGl using sera from a PG patient showing linear BMZ staining in 
amniotic epithelium (left) and with normal control serum showing negative reaction (righr). (X 16) 
plement-derived chemotactic activity by immune complexes oc- 
curred only as a secondary phenomenon, after basal cell damage had 
occurred. Our results would also tend to suggest that complement 
activation is not the primary mode of action of autoimmune tissue 
damage in BP or pemphigus. This, however, appears to be in con- 
trast to PG, where the predominance of complement (actually 
IgGl) and the uniform demonstration of C3 in tissue argue that the 
role of complement activation may be of primary importance in 
tissue injury. 
REFERENCES 
1. Schaumburg-Lever G, Safford OE, Orfanos CE, Lever WF: Herpes 
Gestationis: histology and ultrastructure. Arch Dermatol 107:888- 
892,1973 
2. Provost TT, Tomasi TB: Evidence of complement activation via the 
alternative pathway in skin disease. 1. Herpes gestationis, systemic 
lupus erythematosis and bullous pemphigoid. J Clin Invest 
52:1779-1787, 1973 
3. Kelly SE, Bhogal BS, Wojnarowska F, Black MM: Antigenic cross 
reactivity in skin and amnion in pemphigoid gestationis. Br J Der- 
matol 118:605-611, 1988 
4. Kelly SE, Bhogal BS, Wojnarowska F, Black MM: Ontogeny of a 
pemphigoid gestationis related antigen. Br J Dermatol 118:268, 
1988 
5. Yaoita H, Gullino M, Katz SI: Herpes gestationis. Ultrastructure and 
ultrastuctural localization of in vivo bound complement. J Invest 
Dermatol66:383-388.1985 
6. Carruthers JA,Black MM, Ramnarain N: Immunopathological studies 
in herpes gestationis. Br J Dermatol 96:35-43, 1978 
7. Jordon RE, Heine KG, Tappeiner G, et al: Immunofluorescence stud- 
ies and characterization of the HG factor. J Clin Invest 57:1426- 
1433,1976 
8. Katz SI, Hertz K, Yaoita H: Herpes gestationis. Immunopathology 
and characterization of the HG factor. J Clin Ivest 57:1434- 1441, 
1976 
9. Beutner EH, Nisengard RJ: Defined immunofluorescence in clinical 
immunopathology. In Beutner EH, Chorzelski TP, Bean SF, Jordan 
RE (eds.). Immunopathology of the Skin: Labelled antibody studies. 
Dowden, Hutchison and Ross, Pennsylvania, pp 197-247 
10. Hodge L, Black MM, Ramnarain N, Bhogal BS: Indirect complement 
immunofluorescence in the assessment of bullous pemphigoid, cica- 
tricial pemphigoid and herpes gestationis. ClinExp Dermatol3:61- 
67, 1978 
II. Carruthers JA, Ewins AR: Herpes gestationis: studies on the binding 
characteristics, activity and pathogenic significance of the comple- 
ment fixing factor. Clin Exp Immunol 31:38-44, 1978 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
McConnell I, Munro A, Waldman H: Immunoglobulins as proteins. 
In: The Immune System, 2nd Ed. Blackwell Scientific Publications, 
Oxford 1981, pp 7- 14 
McConnell I, Munro A, Waldman H: Complement. In: The Immune 
System, 2nd Ed. Blackwell Scientific Publications, Oxford, 1981, pp 
40-54 
Bird P, Friedmann PS, Ling N, et al: Subclass distribution of IgG 
autoantibodies in bullous pemphigoid. J Invest Dermatol86:21- 25, 
1986 
Sams WM, Schur PM: Studies of the antibodies in pemphigoid and 
pemphigus. J Lab Clin Med 82: 154 - 249, 1972 
Gammon WR, Merritt CC, Lewis DM, et al: An in vitro model of 
immune complex mediated basement membrane zone separation 
caused by pemphigoid antibodies, leukocytes and complement. J 
Invest Dermatol 78:285 - 290, 1982 
Dahl MV, Falk RJ, Carpenter R, Michael AF: Deposition of the mem- 
brane attack complex of complement in bullous pemphigoid. J In- 
vest Dermatol 82:132-135, 1984 
Jordan RE, Nordby-McFarland JM, Tappeiner G: The complement 
system in bullous pemphigoid. In vitro fixation of properdin by 
pemphigoid antibody. J Clin Lab Immunol 1:59-65, 1978 
Sams WM, Gammon WR: Mechanism of lesion production in pem- 
phigus and pemphigoid. J Am Acad Dermatol 6:431-449, 1982 
Gammon WR, Lewis DM, Carlo JR et al: Pemphigoid antibody me- 
diated attachment of peripheral blood leucocytes at the dermal-epi- 
dermal junction of human skin. J Invest Dermatol 75:334-339, 
1980 
